DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC trimmed its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 3.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 568,462 shares of the medical device company's stock after selling 20,286 shares during the period. DexCom comprises 1.3% of Peregrine Capital Management LLC's investment portfolio, making the stock its 16th biggest holding. Peregrine Capital Management LLC owned approximately 0.14% of DexCom worth $38,820,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in DXCM. Larson Financial Group LLC boosted its holdings in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the period. Nia Impact Advisors LLC lifted its position in shares of DexCom by 1.4% during the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after purchasing an additional 140 shares in the last quarter. Level Four Advisory Services LLC boosted its stake in shares of DexCom by 1.1% in the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after purchasing an additional 150 shares during the period. Covestor Ltd grew its holdings in shares of DexCom by 15.6% in the fourth quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after purchasing an additional 150 shares in the last quarter. Finally, TD Private Client Wealth LLC increased its stake in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on the company. The Goldman Sachs Group started coverage on DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Citigroup reiterated a "buy" rating and issued a $102.00 price target (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Barclays boosted their price target on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Robert W. Baird decreased their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Five research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $98.50.

Insider Activity

In other news, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president directly owned 109,621 shares of the company's stock, valued at $9,329,843.31. This trade represents a 5.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the transaction, the executive vice president directly owned 95,602 shares in the company, valued at $8,057,336.56. This represents a 9.47% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,190 shares of company stock valued at $2,281,732. 0.32% of the stock is owned by insiders.

DexCom Price Performance

NASDAQ:DXCM remained flat at $83.58 during trading hours on Wednesday. 2,867,027 shares of the company were exchanged, compared to its average volume of 4,399,009. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $117.19. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. The firm has a market cap of $32.77 billion, a price-to-earnings ratio of 62.37, a price-to-earnings-growth ratio of 1.78 and a beta of 1.44. The firm's fifty day moving average is $82.80 and its 200-day moving average is $79.71.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. DexCom's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the company posted $0.32 EPS. Research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.